Metformin Does Not Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obesity
A randomized phase III trial (MAST) found metformin did not prolong progression‑free survival in men on active surveillance for low‑risk prostate cancer; an exploratory subgroup showed increased pathologic progression in obese patients.



















